Next Phase Newsletter

A large pharmaceutical company with multiple offices globally is actively seeking partnering and in-licensing opportunities across all developmental stages globally.

The firm’s core commercial expertise and partnering interests are primarily in the hospital care areas. The firm is looking for collaboration in oncology (in therapeutics and diagnostics), autoimmune/inflammatory diseases, novel antibacterial products and diagnostics (particularly in application to Gram-negative organisms), anti-viral, anti-fungal therapeutics, diagnostics for acute hospital care, rare/orphan disease areas, and cell therapies. The firm is seeking to in-license early-stage assets from pre-clinical to Phase I. However, with rare and orphan disease therapeutics, the company will prefer later-stage clinical assets.

The firm seeks to work with companies developing innovative therapeutics and management teams with strong scientific expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A wholly-owned subsidiary of a pharmaceutical and chemical company headquartered in Seoul, South Korea with offices in the USA is actively seeking promising compounds for innovative new drugs that have global market potential. The firm seeks to partner with companies in a wide variety of ways, including licensing, equity investment, joint venture development, etc. depending on the opportunity and strategic fit. The firm is focused on USA-based opportunities.

The firm is focused only on therapeutics, and does not invest in devices, diagnostics, or digital health companies. The firm is most interested in first-in-class (or best-in-class) assets in oncology/immuno-oncology, NASH and other metabolic diseases. The firm is focused on early-stage opportunities, and prefers to invest equity into partnered companies for R&D collaboration.

The firm does not have specific management team requirements and is open to working with all types of management teams. The firm can either lead or co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm based in Canada invests in 3 verticals: information/communications technologies (ICT), foodtech and medtech. The firm raised its latest fund in early 2019. The firm generally looks to make investments in companies ranging from $2 – $5 million initially and up to $10 million over the life of the investment. The firm is focused on Canadian companies, but will work with companies in the Northeastern and Midwestern U.S. as well. The firm aims to make approximately 2-3 new investments per year.

Within the life science space, the firm is looking for medical device and diagnostics companies that have a clear path to FDA approval, and will look at any devices/diagnostics, pre-FDA approval including 510(k) and PMA pathways. In addition to medtech, the firm is also interested in health IT with the focus being on B2B software-centric companies. The firm does not invest into biotech/drug development companies. The firm recently invested in a molecular diagnostics company focused on infectious disease. The firm is looking for companies that have managed to demonstrate market interest in their product prior to investment.

The firm looks to be a very active investor in chosen companies and always pursues a board seat. The firm looks for strong experienced management teams and looks to bring their own entrepreneurial experience to aid in the growth and expansion of companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare company in China headquartered in Shanghai, China focuses on patent licensing, technology acquisition, joint development, etc. The firm seeks new technologies and projects across Greater China, the US, and some European countries.

In the life sciences, the firm is currently looking for innovative therapeutics companies. The firm will focus on assets in five indication areas: oncology, CNS, cardiovascular, metabolic disease and nutritional, and infectious diseases. For the type of modality, the firm is open to companies developing small molecule, biologics, gene therapy and cell therapy. The firm is most interested in products in clinical phase II and phase III stage, but will consider earlier stage companies that show promising technologies.

The firm is interested in privately held life science companies with experienced management teams and innovative technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm that has been actively investing for over 20 years with multiple offices in Europe has over €1 billion in total assets under management and recently closed its first dedicated Health Tech Fund, after successfully investing in the sector from mixed vehicles for more than 20 years. The firm typically invests €1-5 million in early-stage opportunities or up to €10 million in growth-stage opportunities. The firm is currently focused on companies based in Europe.

Within the life science sector, the firm is currently focused on medical technology, diagnostics, life science tools and platforms, and digital health across Europe. The firm is open to opportunities in any indication area and at any phase of development.

The firm is open to investing in companies at early stages with a proof-of-concept, clinically relevant data and/or strong IP positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A transatlantic investor firm headquartered in Europe with additional offices in USA has managed more than $800 million in total assets across six specialized funds. 2 of their funds focus on healthcare service providers based in the Benelux and Germany, and 4 of their funds focus on investing in companies developing therapeutics, medical devices, diagnostics and digital health. The most recent fund closed at $280 million. The firm prefers to invest in clinical stage therapeutics companies and commercial stage diagnostics/medical technology companies. The investment size ranges from $5 million up to $30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large healthcare group that operates 80+ hospitals across Asia, the Middle East and Turkey has an innovation office that acts as a corporate VC arm, which has committed capital of $80 million to invest in the digital health space. The firm typically invests $5-10 million per opportunity, and will invest in companies worldwide that are interested in expanding into Asia.

The firm only invests in the digital health space. The firm is interested in many areas of digital health that are applicable to hospitals, including predictive analytics, genomic data, and AI. The firm does not invest in biopharma or medtech.

The firm will invest globally, and is focused on startups that are interested in expanding into Asia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.